Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Other EventsItem 8.01. Other Events
On June 2, 2017, Dynavax Technologies Corporation issued a press release titled “Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naïve to an Anti-PD-1 or Anti-PD-L1 Therapy.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibit is filed herewith:
99.1 Press Release, dated June 2, 2017, titled “Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naïve to an Anti-PD-1 or Anti-PD-L1 Therapy”
About Dynavax Technologies Corporation (NASDAQ:DVAX)
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage. Dynavax Technologies Corporation (NASDAQ:DVAX) Recent Trading Information
Dynavax Technologies Corporation (NASDAQ:DVAX) closed its last trading session up +0.25 at 5.90 with 1,562,426 shares trading hands.